BLATT LAWRENCE
SEC insider (Form 3/4/5 filer). CIK 0001242110. President and CEO at Aligos Therapeutics, Inc. (ALGS). 4 reported Form 4/5 transactions since Sep 2024; latest on Mar 9, 2026. Located in SOUTH SAN FRANCISCO, CA.
Companies BLATT LAWRENCE has filed insider reports for
- Aligos Therapeutics, Inc. (ALGS): Director, Officer, President and CEO
BLATT LAWRENCE
CIK: 0001242110
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Aligos Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Mar 9, 2026ALGS
Aligos Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
105.8K shares- - Jul 16, 2025ALGS
Aligos Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
179.8K shares- - Feb 28, 2025ALGS
Aligos Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
140.1K shares- - Sep 4, 2024ALGS
Aligos Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
33.9K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Mar 9, 2026 | ALGS Aligos Therapeutics, Inc. | Award Stock Option (Right to Buy) | 105,840 | - | - | Direct |
| Jul 16, 2025 | ALGS Aligos Therapeutics, Inc. | Award Stock Option (Right to Buy) | 179,800 | - | - | Direct |
| Feb 28, 2025 | ALGS Aligos Therapeutics, Inc. | Award Stock Option (Right to Buy) | 140,103 | - | - | Direct |
| Sep 4, 2024 | ALGS Aligos Therapeutics, Inc. | Award Stock Option (Right to Buy) | 33,920 | - | - | Direct |
1-4 of 4 transactions